KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Gross Profit (2017 - 2026)

Aquestive Therapeutics has reported Gross Profit over the past 9 years, most recently at $20.0 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 172.18% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $38.8 million, down 2.22%, while the annual FY2025 figure was $38.8 million, 2.22% down from the prior year.
  • Gross Profit for Q4 2025 was $20.0 million at Aquestive Therapeutics, up from $8.3 million in the prior quarter.
  • Over five years, Gross Profit peaked at $20.0 million in Q4 2025 and troughed at -$2.5 million in Q2 2021.
  • A 5-year average of $7.7 million and a median of $7.7 million in 2021 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: skyrocketed 769.57% in 2021 and later plummeted 65.05% in 2025.
  • Year by year, Gross Profit stood at $7.7 million in 2021, then plummeted by 30.28% to $5.4 million in 2022, then soared by 43.65% to $7.7 million in 2023, then fell by 4.88% to $7.3 million in 2024, then surged by 172.18% to $20.0 million in 2025.
  • Business Quant data shows Gross Profit for AQST at $20.0 million in Q4 2025, $8.3 million in Q3 2025, and $5.4 million in Q2 2025.